Skip to main
CAH

Cardinal Health (CAH) Stock Forecast & Price Target

Cardinal Health (CAH) Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 33%
Buy 58%
Hold 8%
Sell 0%
Strong Sell 0%

Bulls say

Cardinal Health is expected to experience steady growth in key metrics such as free cash flow and adjusted EPS, driven by its diversified portfolio and strong balance sheet. Despite recent challenges, the company is well-positioned for future growth in precision medicine and radiopharmaceuticals, and continues to invest in expanding capacity in these markets. With a commitment to returning capital to shareholders, Cardinal Health is a solid investment option for those with a positive outlook on the healthcare industry.

Bears say

Cardinal Health is a leading pharmaceutical distributor with a significant market share in the US, generating over 90% of its revenue from the distribution of branded, generic, and specialty pharmaceuticals. However, with a changing healthcare landscape, including increased competition and potential changes in drug pricing regulations, Cardinal Health's profitability and cash flow could be adversely impacted. Additionally, their focus on the home health space may not provide sufficient growth opportunities to offset potential headwinds in their core pharmaceutical distribution business. The recent global medical products and distribution turnaround has shown improvement, but the company faces risks related to their exposure to energy and commodity cost fluctuations as well as potential challenges in their generic and biosimilar businesses.

Cardinal Health (CAH) has been analyzed by 12 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 58% recommend Buy, 8% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Cardinal Health and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Cardinal Health (CAH) Forecast

Analysts have given Cardinal Health (CAH) a Buy based on their latest research and market trends.

According to 12 analysts, Cardinal Health (CAH) has a Buy consensus rating as of Aug 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $242.17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $242.17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Cardinal Health (CAH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.